Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to learn if intravenous dexamethasone can help prolong the effect of spinal anesthesia in adults having elective pelvic, urologic, or proctologic surgery. The study also looks at whether dexamethasone improves pain control after surgery and whether it causes any side effects.
The main questions it aims to answer are:
Does intravenous dexamethasone increase how long the spinal anesthesia lasts?
Does it reduce the need for pain medications after surgery?
Does it cause more or fewer side effects compared to a placebo?
In this study:
Participants were randomly assigned to receive either 8 mg of intravenous dexamethasone or a placebo (salt water).
All participants received standard spinal anesthesia with bupivacaine and sufentanil.
Researchers measured how long the spinal anesthesia lasted and when the first pain medication was needed after surgery.
Participants were monitored for side effects such as low blood pressure, nausea, vomiting, and slow heart rate.
Surgeon satisfaction with anesthesia quality was also recorded.
Participants did not receive any additional procedures beyond routine care. The study found that dexamethasone helped prolong the spinal anesthesia and delayed the need for pain relief, without increasing side effects.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intravenous Dexamethasone Group | Experimental | Participants in this arm received 8 mg of intravenous dexamethasone (2 mL) 5 minutes before spinal anesthesia. The spinal anesthesia was performed with 12.5 mg of 0.5% hyperbaric bupivacaine combined with 2.5 µg of sufentanil. The purpose was to evaluate whether intravenous dexamethasone prolongs the duration of sensory and motor block and improves postoperative analgesia. |
|
| Placebo Group | Placebo Comparator | Participants in this arm received 2 mL of isotonic saline intravenously 5 minutes before spinal anesthesia. The spinal anesthesia was performed identically to the intervention group (12.5 mg of hyperbaric bupivacaine + 2.5 µg sufentanil). This arm served as the control group for evaluating the effects of dexamethasone. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dexamethasone | Drug | Single intravenous injection of 8 mg dexamethasone (2 mL) administered 5 minutes before spinal anesthesia. This intervention was tested for its effect on prolonging the duration of sensory and motor blocks induced by hyperbaric bupivacaine combined with sufentanil. The drug was administered under sterile conditions by an anesthesiologist blinded to group allocation. |
| Measure | Description | Time Frame |
|---|---|---|
| Duration of sensory block | The duration of the sensory block was defined as the time from intrathecal injection of the local anesthetic until regression of sensory level to the L1 dermatome, as assessed by pinprick test every 15 minutes postoperatively. This endpoint was selected to evaluate the effect of intravenous dexamethasone on prolonging the duration of spinal anesthesia. | From the time of spinal injection until sensory regression to L1 dermatome (up to 4 hours postoperatively) |
| Measure | Description | Time Frame |
|---|---|---|
| Duration of motor block | The duration of the motor block was defined as the time from intrathecal injection until achieving a modified Bromage score of 3, which corresponds to partial motor recovery (able to move knees). The modified Bromage score was assessed every 15 minutes postoperatively. This measure was used to assess whether intravenous dexamethasone prolongs motor block following spinal anesthesia. |
Not provided
Inclusion Criteria:
ASA physical status I or II
Scheduled for elective pelvic surgery under spinal anesthesia (urologic, inguinal, or proctologic procedures)
Provided informed consent
Exclusion Criteria:
Contraindications to spinal anesthesia
Neurological diseases
Chronic use of corticosteroids or immunosuppressants
BMI > 40 kg/m²
Refusal to participate
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Samia Arfaoui, Medical Doctor | Habib Thameur Hospital | Study Director |
| Kamel Ben Fadhel, Medical Doctor | Habib Thameur Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Habib Thameur Hospital | Tunis | Tunis Governorate | 1001 | Tunisia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003907 | Dexamethasone |
| ID | Term |
|---|---|
| D011246 | Pregnadienetriols |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
Not provided
Not provided
Two-arm, parallel, randomized controlled trial with 1:1 allocation
Not provided
Not provided
The patient, anesthesia provider, surgeon, and outcome assessor were all blinded to group allocation. The syringes were prepared by a resident not involved in the study.
|
| Placebo | Drug | Single intravenous injection of 2 mL isotonic saline (0.9% NaCl) administered 5 minutes before spinal anesthesia. This placebo was used to mimic the dexamethasone injection in the control group. The preparation, volume, and timing were identical to the intervention group to maintain blinding. The saline was administered under sterile conditions by an anesthesiologist blinded to group allocation. |
|
| From the time of spinal injection until modified Bromage score = 3 (up to 4 hours postoperatively) |
| Time to first analgesic request | Time from intrathecal injection to the first request for postoperative analgesia, defined as the moment when the patient reported a pain score ≥ 3 on a visual analog scale (VAS, 0-10). This was recorded in minutes starting from the time of spinal anesthesia. The aim was to assess whether intravenous dexamethasone prolongs the duration of effective postoperative analgesia. | From spinal injection until VAS score ≥ 3 and first analgesic request (up to 6 hours postoperatively) |
| Incidence of adverse events | Adverse events occurring during the surgical procedure were systematically recorded. These included hypotension (systolic BP < 90 mmHg), bradycardia (HR < 50 bpm), nausea, vomiting, pruritus, and any signs of discomfort or neurological complications. All events were recorded as present or absent and compared between the dexamethasone and placebo groups to assess the safety profile of intravenous dexamethasone during spinal anesthesia. | From spinal injection until the end of surgery |
| Surgeon satisfaction score | Surgeon satisfaction with the quality of intraoperative anesthesia was assessed using a binary score (Satisfied / Not satisfied). The evaluation was based on intraoperative conditions such as patient immobility, comfort, and adequacy of anesthesia. The rating was collected at the end of surgery to compare the perceived quality between the dexamethasone and placebo groups. | Immediately after the end of surgery |
| D000072473 |
| Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D013259 | Steroids, Fluorinated |